{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T23:43:20Z","timestamp":1769730200221,"version":"3.49.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.drudis.2014.06.028","type":"journal-article","created":{"date-parts":[[2014,7,3]],"date-time":"2014-07-03T14:17:19Z","timestamp":1404397039000},"page":"1445-1453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Factor IXa as a target for anticoagulation in thrombotic disorders and conditions"],"prefix":"10.1016","volume":"19","author":[{"given":"Dia A.","family":"Smiley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard C.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2014.06.028_bib0005","first-page":"188","article-title":"American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics","volume":"125","author":"Roger","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2014.06.028_bib0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1023\/B:THRO.0000014588.95061.28","article-title":"Remodeling the blood coagulation cascade","volume":"16","author":"Hoffman","year":"2003","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.drudis.2014.06.028_bib0015","doi-asserted-by":"crossref","first-page":"11317","DOI":"10.1016\/S0021-9258(18)99165-9","article-title":"Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation","volume":"266","author":"Lawson","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2014.06.028_bib0020","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1055\/s-0038-1649480","article-title":"Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1+2","volume":"70","author":"Boisclair","year":"1993","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.06.028_bib0025","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V76.4.731.731","article-title":"Factor IX is activated in vivo by the tissue factor mechanism","volume":"76","author":"Bauer","year":"1990","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2014.06.028_bib0030","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1046\/j.1538-7836.2003.00460.x","article-title":"Roles of factor XI, platelets and tissue factor-initiated blood coagulation","volume":"10","author":"Walsh","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.06.028_bib0035","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","article-title":"Haemophilias A and B","volume":"9371","author":"Bolton-Maggs","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2014.06.028_bib0040","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1161\/01.ATV.0000183884.06371.52","article-title":"Tissue-specific hemostasis in mice","volume":"25","author":"Mackman","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.drudis.2014.06.028_bib0045","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/hc0802.104331","article-title":"Direct thrombin inhibitors in acute coronary syndromes: present and future","volume":"105","author":"Weitz","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2014.06.028_bib0050","doi-asserted-by":"crossref","first-page":"23418","DOI":"10.1074\/jbc.272.37.23418","article-title":"Interaction of factor IXa with factor VIIIa. Effects of protease domain Ca2+ binding site, proteolysis in the autolysis loop, phospholipid, and factor X","volume":"272","author":"Mathur","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2014.06.028_bib0055","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1182\/blood.V90.10.3962","article-title":"A coagulation factor IX-knockout mouse model for human hemophilia B","volume":"90","author":"Lin","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2014.06.028_bib0060","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1006\/mthe.2001.0449","article-title":"Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors","volume":"4","author":"Chao","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2014.06.028_bib0065","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1538-7836.2005.01236.x","article-title":"Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice","volume":"3","author":"Wang","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.06.028_bib0070","doi-asserted-by":"crossref","first-page":"16227","DOI":"10.1074\/jbc.271.27.16227","article-title":"Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX","volume":"271","author":"Freedman","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2014.06.028_bib0075","doi-asserted-by":"crossref","first-page":"9796","DOI":"10.1073\/pnas.92.21.9796","article-title":"X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B","volume":"92","author":"Brandstetter","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2014.06.028_bib0080","doi-asserted-by":"crossref","first-page":"25332","DOI":"10.1074\/jbc.271.41.25332","article-title":"Ca2+ binding to the first epidermal growth factor-like domain of human blood coagulation factor IX promotes enzyme activity and factor VIII light chain binding","volume":"271","author":"Lenting","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2014.06.028_bib0085","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1182\/blood.V96.10.3459","article-title":"Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein","volume":"96","author":"Neels","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2014.06.028_bib0090","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0140-6736(51)91163-4","article-title":"Recent history of coronary disease","volume":"1","author":"Morris","year":"1951","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2014.06.028_bib0095","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00041433-199610000-00012","article-title":"Macrophages and atherosclerotic plaque stability","volume":"7","author":"Libby","year":"1996","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.drudis.2014.06.028_bib0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-2006-939550","article-title":"An overview of the structure and function of thrombin","volume":"32","author":"Davie","year":"2006","journal-title":"Semin. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.06.028_bib0105","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1161\/01.CIR.94.6.1226","article-title":"Identification of active tissue factor in human coronary atheroma","volume":"94","author":"Marmur","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2014.06.028_bib0110","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0021-9150(99)00063-5","article-title":"Tissue factor in atherosclerosis","volume":"144","author":"Tremoli","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.drudis.2014.06.028_bib0115","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1309\/QC259F09UNMKVP0R","article-title":"Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events","volume":"126","author":"Yang","year":"2006","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.drudis.2014.06.028_bib0120","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/blood-2005-12-023697","article-title":"Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII","volume":"108","author":"Doggen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2014.06.028_bib0125","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1161\/01.ATV.20.11.2489","article-title":"Activation of clotting factors XI and IX in patients with acute myocardial infarction","volume":"20","author":"Minnema","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.drudis.2014.06.028_bib0130","doi-asserted-by":"crossref","first-page":"20012","DOI":"10.1016\/S0021-9258(19)47211-6","article-title":"Platelet receptor occupancy with factor IXa promotes factor X activation","volume":"264","author":"Ahmad","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2014.06.028_bib0135","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/35025229","article-title":"Thrombin signaling and protease-activated receptors","volume":"407","author":"Coughlin","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2014.06.028_bib0140","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCINTERVENTIONS.109.884478","article-title":"Anticoagulant therapy for percutaneous coronary intervention","volume":"3","author":"Rao","year":"2010","journal-title":"Circ. Cardiovasc. Interv."},{"key":"10.1016\/j.drudis.2014.06.028_bib0145","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1161\/01.CIR.92.9.2579","article-title":"Effects on coagulation and fibrinolysis with reduced versus full systemic heparinization and heparin-coated cardiopulmonary bypass","volume":"92","author":"Ovrum","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2014.06.028_bib0150","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1540-8191.1993.tb00384.x","article-title":"Blood-surface interactions during cardiopulmonary bypass","volume":"8","author":"Edmunds","year":"1993","journal-title":"J. Card. Surg."},{"key":"10.1016\/j.drudis.2014.06.028_bib0155","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0888-6296(89)92642-2","article-title":"Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery","volume":"3","author":"Tanaka","year":"1989","journal-title":"J. Cardiothorac. Anesth."},{"key":"10.1016\/j.drudis.2014.06.028_bib0160","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/ajh.2830480412","article-title":"Hemostatic complications of cardiopulmonary bypass","volume":"48","author":"Colman","year":"1995","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.drudis.2014.06.028_bib0165","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0003-4975(97)01345-3","article-title":"Activation of coagulation and fibrinolysis during cardiothoracic operations","volume":"65","author":"Hunt","year":"1998","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.drudis.2014.06.028_bib0170","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1365-2141.1995.tb05170.x","article-title":"An ELISA for factor X activation peptide: application to the investigation of thrombogenesis in cardiopulmonary bypass","volume":"90","author":"Philippou","year":"1995","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drudis.2014.06.028_bib0175","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1053\/jcan.2003.42","article-title":"Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation","volume":"17","author":"Koster","year":"2003","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"10.1016\/j.drudis.2014.06.028_bib0180","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1055\/s-0038-1649561","article-title":"Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant?","volume":"70","author":"Brister","year":"1993","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.06.028_bib0185","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/0003-4975(95)00668-B","article-title":"Heparin causes platelet dysfunction and induces fibrinolysis before cardiopulmonary bypass","volume":"60","author":"Khuri","year":"1995","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.drudis.2014.06.028_bib0190","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0022-5223(98)70419-2","article-title":"Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog","volume":"115","author":"Spanier","year":"1998","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.drudis.2014.06.028_bib0195","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ymthe.2006.04.006","article-title":"A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery","volume":"14","author":"Nimjee","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.drudis.2014.06.028_bib0200","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/heart.88.3.313","article-title":"Off-pump coronary artery bypass surgery","volume":"88","author":"de Jaegere","year":"2002","journal-title":"Heart"},{"key":"10.1016\/j.drudis.2014.06.028_bib0205","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-5223(98)00437-1","article-title":"Selective anticoagulation with active site-blocked factor IXA suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass","volume":"116","author":"Spanier","year":"1998","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"10.1016\/j.drudis.2014.06.028_bib0210","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.seminhematol.2007.02.004","article-title":"Epidemiology and risk factors for venous thrombosis","volume":"44","author":"Cushman","year":"2007","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.drudis.2014.06.028_bib0215","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood.V86.5.1794.bloodjournal8651794","article-title":"Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation","volume":"86","author":"Hoffman","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2014.06.028_bib0220","doi-asserted-by":"crossref","first-page":"22875","DOI":"10.1074\/jbc.M400531200","article-title":"The significance of circulating factor IXa in blood","volume":"279","author":"Butenas","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2014.06.028_bib0225","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1538-7836.2007.02369.x","article-title":"Microparticle-associated tissue factor activity: a link between cancer and thrombosis?","volume":"5","author":"Tesselaar","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.06.028_bib0230","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/j.1538-7836.2005.01373.x","article-title":"The P-selectin, tissue factor, coagulation triad","volume":"3","author":"Polgar","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.06.028_bib0235","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1056\/NEJM200003093421004","article-title":"High levels of coagulation factor XI as a risk factor for venous thrombosis","volume":"342","author":"Meijers","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.06.028_bib0240","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1055\/s-0037-1614852","article-title":"An inhibitory anti-factor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis","volume":"82","author":"Feuerstein","year":"1999","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.06.028_bib0245","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1160\/TH09-04-0255","article-title":"Genetic fusion to albumin improves the pharmacokinetic properties of factor IX","volume":"102","author":"Metzner","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.06.028_bib0250","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1111\/jth.12421","article-title":"Evidence of clinically significant extravascular stores of factor IX","volume":"11","author":"Feng","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.06.028_bib0255","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1172\/JCI115495","article-title":"Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model","volume":"88","author":"Benedict","year":"1991","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2014.06.028_bib0260","first-page":"1087","article-title":"Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis","volume":"134","author":"Drake","year":"1989","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.drudis.2014.06.028_bib0265","doi-asserted-by":"crossref","first-page":"8481","DOI":"10.1016\/S0021-9258(19)75245-4","article-title":"Kinetics of the activation of bovine coagulation factor X by components of the extrinsic pathway. Kinetic behavior of two-chain factor VII in the presence and absence of tissue factor","volume":"252","author":"Silverberg","year":"1977","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2014.06.028_bib0270","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood.V60.6.1353.1353","article-title":"An alternative extrinsic pathway of human blood coagulation","volume":"60","author":"Marlar","year":"1982","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2014.06.028_bib0275","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2141.1987.tb01303.x","article-title":"In vivo evidence of intravascular binding sites for coagulation factor IX","volume":"66","author":"Stern","year":"1987","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drudis.2014.06.028_bib0280","doi-asserted-by":"crossref","first-page":"20529","DOI":"10.1016\/S0021-9258(19)36713-4","article-title":"The binding of human factor IX to endothelial cells is mediated by residues 3\u201311","volume":"267","author":"Cheung","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2014.06.028_bib0285","doi-asserted-by":"crossref","first-page":"7886","DOI":"10.1021\/bi7004703","article-title":"The heparin-binding exosite is critical to allosteric activation of factor IXa in the intrinsic tenase complex: the role of arginine 165 and factor X","volume":"46","author":"Misenheimer","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.drudis.2014.06.028_bib0290","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0014-5793(02)03507-X","article-title":"Calcium-binding analysis and molecular modeling reveal echis coagulation factor IX\/factor X-binding protein has the Ca-binding properties and Ca ion-independent folding of other C-type lectin-like proteins","volume":"531","author":"Atoda","year":"2002","journal-title":"FEBS Lett."},{"key":"10.1016\/j.drudis.2014.06.028_bib0295","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.bbrc.2005.05.033","article-title":"A C-type lectin-like protein from Agkistrodon acutus venom binds to both platelet glycoprotein Ib and coagulation factor IX\/factor X","volume":"332","author":"Li","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.drudis.2014.06.028_bib0300","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.190.1.91","article-title":"Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage","volume":"190","author":"Choudhri","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drudis.2014.06.028_bib0305","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/00001721-200001000-00004","article-title":"Use of phage display for the generation of human antibodies that neutralize factor IXa function","volume":"11","author":"Suggett","year":"2000","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.drudis.2014.06.028_bib0310","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1161\/hq0302.105375","article-title":"A human antibody that inhibits factor IX\/IXa function potently inhibits arterial thrombosis without increasing bleeding","volume":"22","author":"Refino","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.drudis.2014.06.028_bib0315","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1161\/01.ATV.0000259363.91070.f1","article-title":"Factor IXa inhibitors as novel anticoagulants","volume":"27","author":"Howard","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.drudis.2014.06.028_bib0320","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0049-3848(00)00299-1","article-title":"Comparing the antithrombotic efficacy of a humanized anti-factor IX(a) monoclonal antibody (SB 249417) to the low molecular weight heparin enoxaparin in a rat model of arterial thrombosis","volume":"100","author":"Toomey","year":"2000","journal-title":"Thromb. Res."},{"key":"10.1016\/j.drudis.2014.06.028_bib0325","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1161\/hs0202.102950","article-title":"Inhibition of factor IX(a) is protective in a rat model of thromboembolic stroke","volume":"33","author":"Toomey","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.drudis.2014.06.028_bib0330","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0022-3565(24)35355-8","article-title":"Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys","volume":"292","author":"Benincosa","year":"2000","journal-title":"J. Pharmaco. Exp. Ther."},{"key":"10.1016\/j.drudis.2014.06.028_bib0335","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1538-7836.2007.02872.x","article-title":"Fixit Study Group. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study","volume":"6","author":"Eriksson","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.drudis.2014.06.028_bib0340","doi-asserted-by":"crossref","first-page":"120S","DOI":"10.1378\/chest.11-2294","article-title":"New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Weitz","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.drudis.2014.06.028_bib0345","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.106.668434","article-title":"First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a Phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity","volume":"114","author":"Dyke","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2014.06.028_bib0350","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1161\/CIRCULATIONAHA.107.745687","article-title":"Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease","volume":"117","author":"Chan","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2014.06.028_bib0355","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2217\/fca.12.5","article-title":"The REG1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome","volume":"8","author":"Vavalle","year":"2012","journal-title":"Future Cardiol."},{"key":"10.1016\/j.drudis.2014.06.028_bib0360","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature00963","article-title":"RNA aptamers as reversible antagonists of coagulation factor IXa","volume":"419","author":"Rusconi","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2014.06.028_bib0365","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1093\/eurheartj\/ehr179","article-title":"RADAR Investigators. Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy","volume":"32","author":"Povsic","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.drudis.2014.06.028_bib0370","unstructured":"A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI (Regulate). Available at: http:\/\/clinicaltrials.gov\/show\/NCT01848106"},{"key":"10.1016\/j.drudis.2014.06.028_bib0375","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.06.028_bib0380","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.06.028_bib0385","unstructured":"Lovenox [package insert]. Laval, Quebec.sanofi-aventis Canada Inc. July 2013"},{"key":"10.1016\/j.drudis.2014.06.028_bib0390","unstructured":"Fragmin [package insert]. New York, NY. Pfizer Inc. October 2010"},{"key":"10.1016\/j.drudis.2014.06.028_bib0395","unstructured":"Coumadin [package insert]. Princeton, NJ: Bristol-Myers Squibb. October 2011"},{"key":"10.1016\/j.drudis.2014.06.028_bib0400","unstructured":"Angiomax [package insert]. Parsipanny, NJ; The Medicines Company. May 2013"},{"key":"10.1016\/j.drudis.2014.06.028_bib0405","unstructured":"Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc. January 2013"},{"key":"10.1016\/j.drudis.2014.06.028_bib0410","unstructured":"Acova [package insert]. Research Triangle Park, NC: GlaxoSmithKline Inc. April 2012"},{"key":"10.1016\/j.drudis.2014.06.028_bib0415","unstructured":"Arixtra [package insert]. Research Triangle Park, NC: GlaxoSmithKline Inc. September 2013"},{"key":"10.1016\/j.drudis.2014.06.028_bib0420","unstructured":"Xarelto [package insert]. Titusville, NJ: Janssen Pharmaceuticals Inc. November 2012"},{"key":"10.1016\/j.drudis.2014.06.028_bib0425","unstructured":"Eliquis [package insert]. Princeton, New Jersey: Bristol-Myers Squibb Inc; December 2012"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644614002700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644614002700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:18:47Z","timestamp":1761221927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644614002700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":85,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S1359644614002700"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2014.06.028","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factor IXa as a target for anticoagulation in thrombotic disorders and conditions","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2014.06.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}